DMAC
DiaMedica Therapeutics Inc.Company Information
- Company Name
- DiaMedica Therapeutics Inc.
- CIK
- CIK0001401040
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- DMAC: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- DMAC
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-11-25
- Last sale
- 2022-12-02
- Shares purchased (TTM)
- 4,944,205
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 12,465,314
- Shares outstanding
- 53,894,295
- Ownership
- 23.13%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- 1.50%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents At Carrying Value | 5 | 5 | 16 | 3 | 4 | 3 | 3 | 4 | 14 | 2 | 5 | 2 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 44 | 52 | 61 | 56 | 31 | 37 | 45 | 51 | 55 | 47 | 54 | 48 | ||||||
| Marketable Securities Current | 38 | 46 | 44 | 52 | 26 | 34 | 41 | 46 | 40 | 44 | 48 | 44 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deposits Assets Current | - | - | - | 0 | 0 | 0 | - | - | - | - | - | - | ||||||
| Marketable Securities Noncurrent | - | - | - | - | - | 1 | - | - | - | - | - | 10 | ||||||
| Deferred Costs | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Assets Noncurrent | 1 | 1 | 1 | 1 | 0 | 1 | 2 | 2 | 2 | 2 | 0 | 10 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deposits Assets Noncurrent | - | - | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | - | ||||||
| Assets | 45 | 53 | 61 | 57 | 31 | 39 | 46 | 53 | 57 | 49 | 54 | 58 | ||||||
| Accounts Payable Current | 3 | 3 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Liabilities Current | ||||||||||||||||||
| Accrued Liabilities Current | 4 | 2 | 4 | 3 | 3 | 3 | 4 | 3 | 2 | 2 | 2 | 1 | ||||||
| Liabilities Current | 7 | 6 | 5 | 5 | 4 | 5 | 5 | 4 | 3 | 3 | 3 | 2 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Finance Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 231 | 230 | 229 | 216 | 183 | 182 | 181 | 180 | 179 | 167 | 167 | 166 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 38 | 47 | 56 | 52 | 27 | 34 | 41 | 48 | 53 | 46 | 51 | 56 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -193 | -183 | -173 | -164 | -155 | -148 | -140 | -132 | -126 | -121 | -116 | -110 | ||||||
| Liabilities And Stockholders Equity | 45 | 53 | 61 | 57 | 31 | 39 | 46 | 53 | 57 | 49 | 54 | 58 | ||||||
| Common Stock No Par Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Issued | 54 | 54 | 54 | 52 | 43 | 43 | 43 | 43 | 43 | 38 | 38 | 38 | ||||||
| Shares Outstanding | 54 | 54 | 54 | 52 | 43 | 43 | 43 | 43 | 43 | 38 | 38 | 38 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialDiaMedica Therapeutics Inc. (DMAC) — SEC Financial Statements & Analysis
DiaMedica Therapeutics Inc. (DMAC) is a pharmaceutical preparations company, incorporated in Z4. DiaMedica Therapeutics Inc. trades on Nasdaq as: DMAC. DiaMedica Therapeutics Inc. (DMAC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, DiaMedica Therapeutics Inc. carries a market cap of $379.42M, a P/E ratio of -10.11x, a P/B ratio of 9.90x, an enterprise value of $374.30M, and an EV/EBITDA multiple of -9.55x. On profitability, it posts a Return on Equity (ROE) of -114.62%, a Return on Assets (ROA) of -98.18%, and a Return on Invested Capital (ROIC) of -139.24%. Per share, it reports EPS of $-0.70, free cash flow per share of $-0.59, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 26.91% year-over-year and EPS growth of 1.16% year-over-year. On the balance sheet, it maintains a current ratio of 6.72x, a quick ratio of 6.63x, working capital of $37.72M, a debt-to-equity ratio of 0.17x, a debt ratio of 0.15, free cash flow of $-31.54M (TTM), and net debt of $-5.12M. Figures sourced from SEC EDGAR.
- Market Cap
- $379.42M
- P/E TTM
- -10.11x
- EPS TTM
- $-0.70
- P/B TTM
- 9.90x
- ROE TTM
- -114.62%
- ROA TTM
- -98.18%
- Debt To Equity
- 0.17x
- Free Cash Flow TTM
- $-31.54M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is DiaMedica Therapeutics Inc. in?
DiaMedica Therapeutics Inc. (DMAC) operates in the Pharmaceutical Preparations industry.
What exchange does DMAC trade on?
DiaMedica Therapeutics Inc. (DMAC) trades on the Nasdaq.
Where is DiaMedica Therapeutics Inc. incorporated?
DiaMedica Therapeutics Inc. is incorporated in Canada (Federal Level).
When was DiaMedica Therapeutics Inc. (DMAC)'s most recent SEC filing?
DiaMedica Therapeutics Inc. (DMAC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is DMAC's market cap?
DiaMedica Therapeutics Inc. (DMAC) has a market capitalization of $379.42M as of 2026-06-30.
What is DMAC's EPS (earnings per share)?
DiaMedica Therapeutics Inc. (DMAC)'s trailing twelve month EPS is $-0.70 as of 2026-06-30.
What is DMAC's ROE (return on equity)?
DiaMedica Therapeutics Inc. (DMAC)'s trailing twelve month Return on Equity (ROE) is -114.62% as of 2026-06-30.
What is DMAC's ROA (return on assets)?
DiaMedica Therapeutics Inc. (DMAC)'s trailing twelve month Return on Assets (ROA) is -98.18% as of 2026-06-30.
What is DMAC's ROIC (return on invested capital)?
DiaMedica Therapeutics Inc. (DMAC)'s trailing twelve month Return on Invested Capital (ROIC) is -139.24% as of 2026-06-30.
What is DMAC's EV/EBITDA?
DiaMedica Therapeutics Inc. (DMAC)'s trailing twelve month EV/EBITDA is -9.55x as of 2026-06-30.